'There was and there is no takeover offer': German coronavirus vaccine company CureVac is shooting down viral reports that Trump tried to buy it

• The German biotech company CureVac is denying reports that Trump administration officials attempted to acquire the company.
• "There was and there is no takeover offer from the White House or governmental authorities. Neither to the technology or to CureVac at all as a company," CureVac acting CEO Franz-Wener Haas said on a conference call on Tuesday.
• Visit Business Insider's homepage for more stories.

The Gerrman biotech company working on a coronavirus vaccine has denied reports that the Trump administration made moves to acquire the firm or its research.

CureVac has been shooting down the news reports for several days, and added to the denials in a conference call with investors on Tuesday.

"There was and there is no takeover offer from the White House or governmental authorities. Neither to the technology or to CureVac at all as a company," CureVac acting CEO Franz-Wener Haas said on a conference call on Tuesday.

CureVac gained widespread attention over the weekend after the German newspaper Welt am Sonntag reported that a Trump administration official offered large sums of money for rights to its vaccine, "but only for the USA."

Read more: Everything you need to know about CureVac, the drugmaker working on a coronavirus vaccine that's at the heart of a Trump-Germany controversy

This is a developing story and will be updated.

Featured Digital Health Articles:
- Telehealth Industry: Benefits, Services & Examples
- Value-Based Care Model: Pay-for-Performance Healthcare
- Senior Care & Assisted Living Market Trends
- Smart Medical Devices: Wearable Tech in Healthcare
- AI in Healthcare
- Remote Patient Monitoring Industry: Devices & Market Trends